Botox, a prescription medicine made from a purified bacterial toxin, is injected in tiny amounts to relax facial muscles that crease the skin. It reliably smooths frown lines, crow's feet and forehead lines, with effects fading after about three to four months. Benefits for oiliness, pores and texture rest on small, not fully consistent studies. Main risks (drooping eyelid or brow, headache, bruising) are temporary and depend on injector skill. (Full Review)

Protocol

Standard upper-face doses (onabotulinumtoxinA)

Frown lines 20 U, crow's feet 24 U, forehead plus frown lines 40 U

All three areas 64 U; 4 U per 0.1 mL with a 30–33 gauge needle

Microdroplet (intradermal) technique

20–28 U onabotulinumtoxinA per mL

100–120 tiny skin blebs per side; 30–45 U abobotulinumtoxinA effective for forehead oiliness

Timing and interval

Time of day does not matter

Dosing more often than every 3 months has not been evaluated

Time to effect

Smoother frown, crow's feet and forehead lines

Builds over the first 1–2 weeks

Frown-line response 74% at day 7, 80% at day 30; effect fades over 3–4 months

Smoother neck bands and jawline

By day 14

Benefit at day 14 after a single treatment; trials followed participants for 120 days

Less oily skin and smaller-looking pores

Pore benefit at two weeks only, in one split-face trial

Less forehead oiliness for six months at higher doses; modest, technique-dependent effect

Benefits

High: Smoother frown, crow's feet and forehead lines; lifted mood; less visible facial surgical scars

Medium: Smoother neck bands and jawline; less oily skin and smaller-looking pores; finer skin texture; less facial redness and flushing

Low: Prevention of etched lines with long-term use; softer lip lines

Speculative: Collagen remodeling in sun-damaged skin

Contraindications

Known hypersensitivity to any botulinum toxin product or its ingredients

Infection at the planned injection site

Neuromuscular junction disorders (myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis), unless closely supervised

Pregnancy or breastfeeding

Significant systemic disease (anesthesiologists' ASA physical status class 3 or higher)

Pre-existing swallowing or breathing difficulty

Key Interactions

Aminoglycosides (injectable antibiotics: gentamicin, tobramycin, amikacin)

Neuromuscular blockers used in anesthesia (rocuronium, succinylcholine)

Muscle relaxants (cyclobenzaprine, baclofen, tizanidine)

Anticholinergic drugs (medicines that block acetylcholine: oxybutynin, diphenhydramine, scopolamine)

Other botulinum toxin products (abobotulinumtoxinA, incobotulinumtoxinA, rimabotulinumtoxinB; within months)

Anticoagulant and antiplatelet drugs (warfarin, apixaban, clopidogrel, aspirin; theoretical)

Over-the-counter nonsteroidal anti-inflammatory drugs (ibuprofen, naproxen; theoretical)

Vitamin E, fish oil, ginkgo, garlic supplements (theoretical for fish oil, ginkgo, garlic)

Zinc with phytase (an enzyme that frees zinc from plant phytate)

Copper, magnesium and calcium supplements (theoretical)

Facial massage, microcurrent or pressure devices (first hours; theoretical)

Risk & Side Effects

High: Drooping eyelid or brow and other unwanted muscle weakness; headache

Medium: Injection-site bruising; eyelid swelling and dry eye

Low: Antibody-related loss of response; dampened emotional processing; muscle thinning with repeated treatment; botulism-like illness from counterfeit or misused toxin; serious allergic reactions; irregular heart rhythm and heart attack

Speculative: Theoretical infection transmission from albumin

Monitoring

Marker	Target	Why
Facial Wrinkle Scale grade (0–3) at maximum contraction and at rest	Grade 0–1 (none or mild)	Tracks the main benefit
Eyelid position (marginal reflex distance, MRD1)	No established target; track change from own baseline	Detects eyelid or brow drooping that changes dosing or placement
Urine or blood pregnancy test (hCG)	Negative	A positive result stops treatment
Skin oil (sebum) reading, forehead or cheek, for in-skin use	No established target; track change from own baseline	Tracks oil reduction
Neutralizing antibody test (only after loss of response)	Negative	A positive result changes product or stops use

Cadence: Review 2 weeks after each treatment; repeat photographs at 3–4 months before each new session; comparison with baseline photographs every 12 months; antibody test only if a previously working treatment stops working

Qualitative Assessment

Satisfaction with appearance and perceived age in photographs
Natural-looking expression versus a "frozen" look
Eyelid heaviness, brow position and smile symmetry
Headache, bruising or eye dryness after sessions
Perceived oiliness, pore visibility and smoothness (for in-skin use)
Mood and emotional responsiveness

Botox for Skin Rejuvenation

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment